|
1
|
O'Flaherty JD, Barr M, Fennell D, Richard
D, Reynolds J, O'Leary J and O'Byrne K: The cancer stem-cell
hypothesis: Its emerging role in lung cancer biology and its
relevance for future therapy. J Thorac Oncol. 7:1880–1890. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leon G, MacDonagh L, Finn SP, Cuffe S and
Barr MP: Cancer stem cells in drug resistant lung cancer: Targeting
cell surface markers and signaling pathways. Pharmacol Ther.
158:71–90. 2016. View Article : Google Scholar
|
|
3
|
MacDonagh L, Gray SG, Breen E, Cuffe S,
Finn SP, O'Byrne KJ and Barr MP: Lung cancer stem cells: The root
of resistance. Cancer Lett. 372:147–156. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu T, Xu F, Du X, Lai D, Liu T, Zhao Y,
Huang Q, Jiang L, Huang W, Cheng W, et al: Establishment and
characterization of multidrug resistant, prostate
carcinoma-initiating stem-like cells from human prostate cancer
cell lines 22RV1. Mol Cell Biochem. 340:265–273. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fang DD, Cao J, Jani JP, Tsaparikos K,
Blasina A, Kornmann J, Lira ME, Wang J, Jirout Z, Bingham J, et al:
Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis
resistance in cancer stem cell-like cells enriched with tumor
spheroids from a non-small cell lung cancer cell line. Front Med.
7:462–476. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vlashi E and Pajonk F: The metabolic state
of cancer stem cells - a valid target for cancer therapy? Free
Radic Biol Med. 79:264–268. 2015. View Article : Google Scholar
|
|
7
|
Pfeiffer MJ and Schalken JA: Stem cell
characteristics in prostate cancer cell lines. Eur Urol.
57:246–254. 2010. View Article : Google Scholar
|
|
8
|
Lagadec C, Vlashi E, Della Donna L,
Dekmezian C and Pajonk F: Radiation-induced reprogramming of breast
cancer cells. Stem Cells. 30:833–844. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ghisolfi L, Keates AC, Hu X, Lee DK and Li
CJ: Ionizing radiation induces stemness in cancer cells. PLoS One.
7:e436282012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li P, Yang R and Gao WQ: Contributions of
epithelial-mesen-chymal transition and cancer stem cells to the
development of castration resistance of prostate cancer. Mol
Cancer. 13:552014. View Article : Google Scholar
|
|
11
|
Brown MD, Gilmore PE, Hart CA, Samuel JD,
Ramani VA, George NJ and Clarke NW: Characterization of benign and
malignant prostate epithelial Hoechst 33342 side populations.
Prostate. 67:1384–1396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Antonio V, Brouillet A, Janvier B, Monne
C, Bereziat G, Andreani M and Raymondjean M: Transcriptional
regulation of the rat type IIA phospholipase A2 gene by cAMP and
interleukin-1beta in vascular smooth muscle cells: Interplay of the
CCAAT/enhancer binding protein (C/EBP), nuclear factor-kappaB and
Ets transcription factors. Biochem J. 368:415–424. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong Z, Liu Y, Scott KF, Levin L, Gaitonde
K, Bracken RB, Burke B, Zhai QJ, Wang J, Oleksowicz L, et al:
Secretory phospholipase A2-IIa is involved in prostate cancer
progression and may potentially serve as a biomarker for prostate
cancer. Carcinogenesis. 31:1948–1955. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cummings BS: Phospholipase A2 as targets
for anti-cancer drugs. Biochem Pharmacol. 74:949–959. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Triggiani M, Granata F, Giannattasio G and
Marone G: Secretory phospholipases A2 in inflammatory and allergic
diseases: Not just enzymes. J Allergy Clin Immunol. 116:1000–1006.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saegusa J, Akakura N, Wu CY, Hoogland C,
Ma Z, Lam KS, Liu FT, Takada YK and Takada Y: Pro-inflammatory
secretory phospholipase A2 type IIA binds to integrins alphavbeta3
and alpha4beta1 and induces proliferation of monocytic cells in an
integrin-dependent manner. J Biol Chem. 283:26107–26115. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Triggiani M, Granata F, Balestrieri B,
Petraroli A, Scalia G, Del Vecchio L and Marone G: Secretory
phospholipases A2 activate selective functions in human
eosinophils. J Immunol. 170:3279–3288. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tada K, Murakami M, Kambe T and Kudo I:
Induction of cyclooxygenase-2 by secretory phospholipases A2 in
nerve growth factor-stimulated rat serosal mast cells is
facilitated by interaction with fibroblasts and mediated by a
mechanism independent of their enzymatic functions. J Immunol.
161:5008–5015. 1998.PubMed/NCBI
|
|
19
|
Cupillard L, Mulherkar R, Gomez N, Kadam
S, Valentin E, Lazdunski M and Lambeau G: Both group IB and group
IIA secreted phospholipases A2 are natural ligands of the mouse
180-kDa M-type receptor. J Biol Chem. 274:7043–7051. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nicolas JP, Lambeau G and Lazdunski M:
Identification of the binding domain for secretory phospholipases
A2 on their M-type 180-kDa membrane receptor. J Biol Chem.
270:28869–28873. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scott KF, Sajinovic M, Hein J, Nixdorf S,
Galettis P, Liauw W, de Souza P, Dong Q, Graham GG and Russell PJ:
Emerging roles for phospholipase A2 enzymes in cancer. Biochimie.
92:601–610. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Meyer AM, Dwyer-Nield LD, Hurteau GJ,
Keith RL, O'Leary E, You M, Bonventre JV, Nemenoff RA and Malkinson
AM: Decreased lung tumorigenesis in mice genetically deficient in
cytosolic phospholipase A2. Carcinogenesis. 25:1517–1524. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kallajoki M, Alanen KA, Nevalainen M and
Nevalainen TJ: Group II phospholipase A2 in human male reproductive
organs and genital tumors. Prostate. 35:263–272. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang J, Neubauer BL, Graff JR, Chedid M,
Thomas JE, Roehm NW, Zhang S, Eckert GJ, Koch MO, Eble JN, et al:
Expression of group IIA secretory phospholipase A2 is elevated in
prostatic intraepithelial neoplasia and adenocarcinoma. Am J
Pathol. 160:667–671. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Graff JR, Konicek BW, Deddens JA, Chedid
M, Hurst BM, Colligan B, Neubauer BL, Carter HW and Carter JH:
Expression of group IIa secretory phospholipase A2 increases with
prostate tumor grade. Clin Cancer Res. 7:3857–3861. 2001.PubMed/NCBI
|
|
26
|
Dong Z, Liu Y, Levin L, Oleksowicz L, Wang
J and Lu S: Vav3 oncogene is involved in regulation of secretory
phospholipase A2-IIa expression in prostate cancer. Oncol Rep.
25:1511–1516. 2011.PubMed/NCBI
|
|
27
|
Sved P, Scott KF, McLeod D, King NJ, Singh
J, Tsatralis T, Nikolov B, Boulas J, Nallan L, Gelb MH, et al:
Oncogenic action of secreted phospholipase A2 in prostate cancer.
Cancer Res. 64:6934–6940. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mirtti T, Laine VJ, Hiekkanen H, Hurme S,
Rowe O, Nevalainen TJ, Kallajoki M and Alanen K: Group IIA
phospholipase A as a prognostic marker in prostate cancer:
Relevance to clinicopathological variables and disease-specific
mortality. APMIS. 117:151–161. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oleksowicz L, Liu Y, Bracken RB, Gaitonde
K, Burke B, Succop P, Levin L, Dong Z and Lu S: Secretory
phospholipase A2-IIa is a target gene of the HER/HER2-elicited
pathway and a potential plasma biomarker for poor prognosis of
prostate cancer. Prostate. 72:1140–1149. 2012. View Article : Google Scholar :
|
|
30
|
Kupert E, Anderson M, Liu Y, Succop P,
Levin L, Wang J, Wikenheiser-brokamp K, Chen P, Pinney SM,
Macdonald T, et al: Plasma secretory phospholipase A2-IIa as a
potential biomarker for lung cancer in patients with solitary
pulmonary nodules. BMC Cancer. 11:5132011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Menschikowski M, Hagelgans A, Schuler U,
Froeschke S, Rosner A and Siegert G: Plasma levels of phospholipase
A2-IIA in patients with different types of malignancies: Prognosis
and association with inflammatory and coagulation biomarkers.
Pathol Oncol Res. 19:839–846. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dong Z, Meller J, Succop P, Wang J,
Wikenheiser-Brokamp K, Starnes S and Lu S: Secretory phospholipase
A2-IIa upregulates HER/HER2-elicited signaling in lung cancer
cells. Int J Oncol. 45:978–984. 2014.PubMed/NCBI
|
|
33
|
Mimeault M, Hauke R, Mehta PP and Batra
SK: Recent advances in cancer stem/progenitor cell research:
Therapeutic implications for overcoming resistance to the most
aggressive cancers. J Cell Mol Med. 11:981–1011. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schneider MR and Yarden Y: The EGFR-HER2
module: A stem cell approach to understanding a prime target and
driver of solid tumors. Oncogene. 35:2949–2960. 2016. View Article : Google Scholar :
|
|
35
|
Singh S, Trevino J, Bora-Singhal N,
Coppola D, Haura E, Altiok S and Chellappan SP: EGFR/Src/Akt
signaling modulates Sox2 expression and self-renewal of stem-like
side-population cells in non-small cell lung cancer. Mol Cancer.
11:732012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lu S, Tsai SY and Tsai MJ: Molecular
mechanisms of androgen- independent growth of human prostate cancer
LNCaP-AI cells. Endocrinology. 140:5054–5059. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ho MM, Ng AV, Lam S and Hung JY: Side
population in human lung cancer cell lines and tumors is enriched
with stem-like cancer cells. Cancer Res. 67:4827–4833. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z,
Stass SA and Jiang F: ALDH1A1 is a marker for malignant prostate
stem cells and predictor of prostate cancer patients' outcome. Lab
Invest. 90:234–244. 2010. View Article : Google Scholar
|
|
39
|
Doherty RE, Haywood-Small SL, Sisley K and
Cross NA: Aldehyde dehydrogenase activity selects for the holoclone
phenotype in prostate cancer cells. Biochem Biophys Res Commun.
414:801–807. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Marcato P, Dean CA, Giacomantonio CA and
Lee PW: Aldehyde dehydrogenase: Its role as a cancer stem cell
marker comes down to the specific isoform. Cell Cycle.
10:1378–1384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Januchowski R, Wojtowicz K and Zabel M:
The role of aldehyde dehydrogenase (ALDH) in cancer drug
resistance. Biomed Pharmacother. 67:669–680. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Singh S, Brocker C, Koppaka V, Chen Y,
Jackson BC, Matsumoto A, Thompson DC and Vasiliou V: Aldehyde
dehydrogenases in cellular responses to oxidative/electrophilic
stress. Free Radic Biol Med. 56:89–101. 2013. View Article : Google Scholar :
|
|
43
|
Wu A, Luo W, Zhang Q, Yang Z, Zhang G, Li
S and Yao K: Aldehyde dehydrogenase 1, a functional marker for
identifying cancer stem cells in human nasopharyngeal carcinoma.
Cancer Lett. 330:181–189. 2013. View Article : Google Scholar
|
|
44
|
Nishida S, Hirohashi Y, Torigoe T,
Kitamura H, Takahashi A, Masumori N, Tsukamoto T and Sato N: Gene
expression profiles of prostate cancer stem cells isolated by
aldehyde dehydrogenase activity assay. J Urol. 188:294–299. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nishida S, Hirohashi Y, Torigoe T, Inoue
R, Kitamura H, Tanaka T, Takahashi A, Asanuma H, Masumori N,
Tsukamoto T, et al: Prostate cancer stem-like
cells/cancer-initiating cells have an autocrine system of
hepatocyte growth factor. Cancer Sci. 104:431–436. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jiang F, Qiu Q, Khanna A, Todd NW, Deepak
J, Xing L, Wang H, Liu Z, Su Y, Stass SA, et al: Aldehyde
dehydrogenase 1 is a tumor stem cell-associated marker in lung
cancer. Mol Cancer Res. 7:330–338. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mimeault M and Batra SK: Recent progress
on tissue-resident adult stem cell biology and their therapeutic
implications. Stem Cell Rev. 4:27–49. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hu R, Dunn TA, Wei S, Isharwal S, Veltri
RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, et al:
Ligand-independent androgen receptor variants derived from splicing
of cryptic exons signify hormone-refractory prostate cancer. Cancer
Res. 69:16–22. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dehm SM, Schmidt LJ, Heemers HV, Vessella
RL and Tindall DJ: Splicing of a novel androgen receptor exon
generates a constitutively active androgen receptor that mediates
prostate cancer therapy resistance. Cancer Res. 68:5469–5477. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Munoz M, Henderson M, Haber M and Norris
M: Role of the MRP1/ABCC1 multidrug transporter protein in cancer.
IUBMB Life. 59:752–757. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Modok S, Mellor HR and Callaghan R:
Modulation of multidrug resistance efflux pump activity to overcome
chemoresistance in cancer. Curr Opin Pharmacol. 6:350–354. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Signore M, Ricci-Vitiani L and De Maria R:
Targeting apoptosis pathways in cancer stem cells. Cancer Lett.
332:374–382. 2013. View Article : Google Scholar
|
|
53
|
Bennett DT, Deng XS, Yu JA, Bell MT,
Mauchley DC, Meng X, Reece TB, Fullerton DA and Weyant MJ: Cancer
stem cell phenotype is supported by secretory phospholipase A2 in
human lung cancer cells. Ann Thorac Surg. 98:439–445; discussion
445–436. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Di Lorenzo G, Tortora G, D'Armiento FP, De
Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De
Placido S, Catalano G, et al: Expression of epidermal growth factor
receptor correlates with disease relapse and progression to
androgen-independence in human prostate cancer. Clin Cancer Res.
8:3438–3444. 2002.PubMed/NCBI
|
|
55
|
Shi Y, Brands FH, Chatterjee S, Feng AC,
Groshen S, Schewe J, Lieskovsky G and Cote RJ: Her-2/neu expression
in prostate cancer: High level of expression associated with
exposure to hormone therapy and androgen independent disease. J
Urol. 166:1514–1519. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Osman I, Scher HI, Drobnjak M, Verbel D,
Morris M, Agus D, Ross JS and Cordon-Cardo C: HER-2/neu (p185neu)
protein expression in the natural or treated history of prostate
cancer. Clin Cancer Res. 7:2643–2647. 2001.PubMed/NCBI
|
|
57
|
Signoretti S, Montironi R, Manola J,
Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L,
et al: Her-2-neu expression and progression toward androgen
independence in human prostate cancer. J Natl Cancer Inst.
92:1918–1925. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yeh S, Lin HK, Kang HY, Thin TH, Lin MF
and Chang C: From HER2/Neu signal cascade to androgen receptor and
its coacti-vators: A novel pathway by induction of androgen target
genes through MAP kinase in prostate cancer cells. Proc Natl Acad
Sci USA. 96:5458–5463. 1999. View Article : Google Scholar
|
|
59
|
Craft N, Shostak Y, Carey M and Sawyers
CL: A mechanism for hormone-independent prostate cancer through
modulation of androgen receptor signaling by the HER-2/neu tyrosine
kinase. Nat Med. 5:280–285. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
60
|
Schulze WX, Deng L and Mann M:
Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol
Syst Biol. 1:2005 00082005. View Article : Google Scholar
|
|
61
|
Hsieh AC and Moasser MM: Targeting HER
proteins in cancer therapy and the role of the non-target HER3. Br
J Cancer. 97:453–457. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Tsao MS, Sakurada A, Cutz JC, Zhu CQ,
Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, et
al: Erlotinib in lung cancer - molecular and clinical predictors of
outcome. N Engl J Med. 353:133–144. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Patel MI, Singh J, Niknami M, Kurek C, Yao
M, Lu S, Maclean F, King NJ, Gelb MH, Scott KF, et al: Cytosolic
phospholipase A2-alpha: A potential therapeutic target for prostate
cancer. Clin Cancer Res. 14:8070–8079. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Belinsky GS, Rajan TV, Saria EA, Giardina
C and Rosenberg DW: Expression of secretory phospholipase A2 in
colon tumor cells potentiates tumor growth. Mol Carcinog.
46:106–116. 2007. View Article : Google Scholar
|
|
65
|
Hernández M, Martín R, García-Cubillas MD,
Maeso- Hernández P and Nieto ML: Secreted PLA2 induces
proliferation in astrocytoma through the EGF receptor: Another
inflammation-cancer link. Neuro-oncol. 12:1014–1023. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Martín R, Hernández M, Ibeas E, Fuentes L,
Salicio V, Arnés M and Nieto ML: Secreted phospholipase A2-IIA
modulates key regulators of proliferation on astrocytoma cells. J
Neurochem. 111:988–999. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Valentin E and Lambeau G: Increasing
molecular diversity of secreted phospholipases A(2) and their
receptors and binding proteins. Biochim Biophys Acta. 1488:59–70.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Lambeau G and Lazdunski M: Receptors for a
growing family of secreted phospholipases A2. Trends Pharmacol Sci.
20:162–170. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hernández M, Burillo SL, Crespo MS and
Nieto ML: Secretory phospholipase A2 activates the cascade of
mitogen-activated protein kinases and cytosolic phospholipase A2 in
the human astrocytoma cell line 1321N1. J Biol Chem. 273:606–612.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Park DW, Kim JR, Kim SY, Sonn JK, Bang OS,
Kang SS, Kim JH and Baek SH: Akt as a mediator of secretory
phospholipase A2 receptor-involved inducible nitric oxide synthase
expression. J Immunol. 170:2093–2099. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ibeas E, Fuentes L, Martín R, Hernández M
and Nieto ML: Inflammatory protein sPLA(2)-IIA abrogates
TNFalpha-induced apoptosis in human astroglioma cells: Crucial role
of ERK. Biochim Biophys Acta. 1793:1837–1847. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Morgenbesser SD, McLaren RP, Richards B,
Zhang M, Akmaev VR, Winter SF, Mineva ND, Kaplan-Lefko PJ, Foster
BA, Cook BP, et al: Identification of genes potentially involved in
the acquisition of androgen-independent and metastatic tumor growth
in an autochthonous genetically engineered mouse prostate cancer
model. Prostate. 67:83–106. 2007. View Article : Google Scholar
|
|
73
|
Yu JA, Mauchley D, Li H, Meng X, Nemenoff
RA, Fullerton DA and Weyant MJ: Knockdown of secretory
phospholipase A2 IIa reduces lung cancer growth in vitro and in
vivo. J Thorac Cardiovasc Surg. 144:1185–1191. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Larzabal L, El-Nikhely N, Redrado M,
Seeger W, Savai R and Calvo A: Differential effects of drugs
targeting cancer stem cell (CSC) and non-CSC populations on lung
primary tumors and metastasis. PLoS One. 8:e797982013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lopez-Ayllon BD, Moncho-Amor V, Abarrategi
A, Ibañez de Cáceres I, Castro-Carpeño J, Belda-Iniesta C, Perona R
and Sastre L: Cancer stem cells and cisplatin-resistant cells
isolated from non-small-lung cancer cell lines constitute related
cell populations. Cancer Med. 3:1099–1111. 2014. View Article : Google Scholar : PubMed/NCBI
|
